Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Summary
The purpose of this phase I/II clinical trial is to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal (GI) Cancer.
General Information
NCT#: NCT04426669
Study ID: 2019LS002
Trial Phase: Phase I/II
Trial Sponsor: Intima Bioscience, Inc.
Therapies Used in This Trial: Cyclophosphamide, Aldesleukin, Fludarabine, Autologous tumor infiltrating lymphocytes (TIL)
Sign In